RxDoctor Payments Data

Alfredo Melgar, MD

General Practice · Miami, FLNPI 1093981912

Payments from drug & device makers

$1,846in general payments, 2019–2025

Across 47 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$363
  • Abbott$345
  • Teva Pharmaceuticals USA, Inc.$231
  • Sunovion Pharmaceuticals Inc.$168
  • Avanir Pharmaceuticals, Inc.$127
  • AbbVie$117
  • plus $494 from 13 others

What the payments were for

  • Food & beverage$1,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,846 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$1,296,498
Medicare patients
1,122
Services billed
15,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate220$1,500,103
EliquisApixaban2,299$711,102
NuplazidPimavanserin Tartrate69$168,889
GemtesaVibegron504$132,625
XareltoRivaroxaban425$124,658
TrulicityDulaglutide130$104,091
EntrestoSacubitril/Valsartan257$88,866
OzempicSemaglutide77$74,522
JanuviaSitagliptin Phosphate152$54,735
Budesonide283$47,301
JardianceEmpagliflozin118$43,868
Memantine Hcl795$40,549
JulucaDolutegravir/Rilpivirine11$40,344
NuedextaDextromethorphan Hbr/Quinidine54$40,214
ProcritEpoetin Alfa61$40,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$711,1022,299 claims
Johnson & JohnsonXarelto, Procrit$363$164,694486 claims
Sumitomo Pharma America, Inc.Gemtesa$64$132,625504 claims
Lilly USA, LLCTrulicity$34$104,091130 claims
NovartisEntresto$29$88,866257 claims
Novo NordiskOzempic$22$74,52277 claims
AstraZenecaFarxiga, Brilinta$21$43,777155 claims
Avanir Pharmaceuticals, Inc.Nuedexta$127$40,21454 claims
AbbVieLinzess$117$15,00821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →